In a nutshell The authors determined the value of bone biomarkers in predicting poor survival in patients with hormone resistant prostate cancer. Some background Hormone therapy is a common treatment for prostate cancer. It targets the male sex hormones active in prostate cancer, such as testosterone. Some patients can develop...
Read More
In a nutshell This paper reviewed various strategies of preventing resistance to endocrine therapy. Some background Receptors are proteins found on cells that when activated can lead to cell growth and division. Estrogen receptors (protein found on cell) are one such example. Endocrine therapy is given to patients who have breast cancer with...
Read MoreIn a nutshell The present article reviews new and prospective treatments for castration-resistant prostate cancer (CRPC). Sipuleucel-T, Cabazitaxel, Denosumab and Abiraterone are novel therapies approved in the last few years for CRPC, while several other therapeutic agents such as MDV3100, Alpharadin and...
Read More
In a nutshell The present study assessed the efficiency of a drug named Denosumab in delaying the spread of prostate cancer to the bone in men with resistant prostate cancer (not responding to hormone therapy and surgery). The results show that the drug tested delayed bone involvement by few months. Some background Bone metastases are...
Read More
